Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction
Authors:
- Tami LivnatTLTami Livnat
- Yehonatan WeinbergerYWYehonatan Weinberger
- José A. FernándezJFJosé A. Fernández
- Alaa BashirABAlaa Bashir
- Gil Ben-DavidGBGil Ben-David
- Dahlia PalevskiDPDahlia Palevski
- Sarina Levy-MendelovichSLSarina Levy-Mendelovich
- Gili KenetGili Kenet
- Ivan BudnikIBIvan Budnik
- Yael NisgavYNYael Nisgav
- John H. GriffinJGJohn H. Griffin
- Dov WeinbergerDWDov Weinberger
Open Access
- 26 February 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (3) , 358
Abstract
The activated protein C (APC) ability to inhibit choroidal neovascularization (CNV) growth and leakage was recently shown in a murine model. A modified APC, 3K3A-APC, was designed to reduce anticoagulant activity while maintaining full cytoprotective properties, thus diminishing bleeding risk. We aimed to study the ability of 3K3A-APC to induce regression of CNV and evaluate vascular endothelial growth factor (VEGF) role in APC’s activities in the retina. CNV was induced by laser photocoagulation on C57BL/6J mice. APC and 3K3A-APC were injected intravitreally after verification of CNV presence. CNV volume and vascular penetration were evaluated on retinal pigmented epithelium (RPE)-choroid flatmount by fluorescein isothiocyanate (FITC)-dextran imaging. VEGF levels were measured using immunofluorescence anti-VEGF staining. We found that 3K3A-APC induced regression of pre-existing CNV. VEGF levels, measured in the CNV lesion sites, significantly decreased upon APC and 3K3A-APC treatment. Reduction in VEGF was sustained 14 days post a single APC injection. As 3K3A-APC retained APCs’ activities, we conclude that the anticoagulant properties of APC are not mandatory for APC activities in the retina and that VEGF reduction may contribute to the protective effects of APC and 3K3A-APC. Our results highlight the potential use of 3K3A-APC as a novel treatment for CNV and other ocular pathologies.Keywords
Funding Information
- National Institutes of Health (R01 HL142975)
- Tel Aviv University Research Authority Meirbaum foundation (0601243983)
- Claire and Amédée Maratier Institute for the Study of Blindness and Visual Disorders, Tel Aviv University (32003197000)
This publication has 42 references indexed in Scilit:
- Suppression and Regression of Choroidal Neovascularization in Mice by a Novel CCR2 Antagonist, INCB3344PLOS ONE, 2011
- Cytoprotective protein C pathways and implications for stroke and neurological disordersTrends in Neurosciences, 2011
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProceedings of the National Academy of Sciences, 2009
- Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1Journal of Neuroscience, 2008
- Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healingWound Repair and Regeneration, 2005
- Gene Expression Profiling of Inflamed Human Endothelial Cells and Influence of Activated Protein CCirculation, 2004
- Activated protein C variants with normal cytoprotective but reduced anticoagulant activityBlood, 2004
- Activated Protein C Induces Endothelial Cell Proliferation by Mitogen-Activated Protein Kinase Activation In Vitro and Angiogenesis In VivoCirculation Research, 2004
- Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytesCytokine, 2004
- Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner ChoriocapillarisThe American Journal of Pathology, 1999